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Abstract
Aim The paper aims to develop a model of translational research in
which service user and other stakeholder involvement are central
to each phase.
Background Translational is the current medical buzzword: trans-
lational research has been termed bench to bedside research and
promises to fast-track biomedical advances in the service of patient
beneﬁt. Models usually conceive of translational research as a
pipeline that is divided into phases: the early phase is characterized
as the province of basic scientists and laboratory-based clinical
researchers; the later phases focus on the implementation, dissemi-
nation and diﬀusion of health applications. If service user
involvement is mentioned, it is usually restricted to these later
phases.
Methods The paper critically reviews existing literature on transla-
tional research and medicine. The authors develop a theoretical
argument that addresses why a reconceptualization of translational
research is required on scientiﬁc, ethical and pragmatic grounds.
Results The authors reconceptualize the model of translational
research as an interlocking loop rather than as a pipeline, one in
which service user and other stakeholder involvement feed into each
of its elements. The authors demonstrate that for the interlocking
loop model of translational research to be materialized in practice
will require changes in how health research is structured and
organized.
Conclusion The authors demonstrate the scientiﬁc, ethical and
pragmatic beneﬁts of involving service users in every phase of
translational research. The authors reconceptualized model of
translational research contributes to theoretical and policy debates
regarding both translational research and service user involvement.
doi: 10.1111/j.1369-7625.2011.00681.x
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The turn to translation
Translational research aims to translate ﬁndings
from basic research more quickly and eﬃciently
into clinical and health-care practice. It is fre-
quently given the shorthand from bench to
bedside: in other words, such research is
intended to ease the path from laboratory
experiments through to clinical trials to patient
(and population-level) interventions and appli-
cations. The concept of translational research
emerged in the 1990s in oncology, speciﬁcally
with regard to attempts to ﬁnd new drugs. In
2003, the National Institutes of Health (NIH) in
the United States raised the term to interna-
tional prominence with the announcement of its
new Roadmap, the third stream of which cen-
tred on translational research.1 Since then, other
countries have prioritized translational research
(e.g. Englands National Institute for Health
Research (NIHR) has funded 12 biomedical
research centres and 16 research units focused
on translat[ing] fundamental biomedical
research into clinical research that beneﬁts
patients;2 the European Commission Seventh
Framework health budget of €6bn includes a
strong focus on translational research).3 Trans-
lational research is therefore likely to be inﬂu-
ential for some time to come – both as a vision
and as a way of structuring and funding research
and health care.
Why the turn to translational research? While
there have been extraordinary advances in the
basic sciences in the last few decades (e.g. the
mapping of the human genome, the vigorous
growth of the neurosciences), there is concern
that this progress has not led to many signiﬁcant
cures and that a valley of death4 has opened
between basic and clinical research. Contopou-
los-Ioannidis et al.,5 for example, found 101
articles published in basic science journals
between 1979 and 1983 that explicitly stated that
the technologies studied had novel therapeutic
or preventive promise; by 2002, only ﬁve of
those ﬁndings were licensed for clinical use.
Translational research hopes to cross the valley
of death and reduce the frequency of ﬁndings
being lost in translation.6
The core instruments of translational research
are biomarkers. Biomarkers are characteristics
that are objectively measured and evaluated as
… indicator[s] of normal biological processes,
pathogenic processes, or pharmacologic
responses to a therapeutic intervention.7 In
other words, biomarkers are intended to assist in
understanding the causal pathways through
which particular conditions develop, individuals
susceptibility to developing particular condi-
tions, and individuals responses to treatments
(most commonly pharmacological interven-
tions). Biomarkers lie at the heart of the attempt
to install a new era of personalized medicine, in
which it is hoped that they will be able to predict
with much greater precision the development of
a disease and allow ﬁne-tuning of appropriate
therapeutic strategies for increasingly speciﬁc
patient subgroups. Translational research cer-
tainly encompasses much research that is not
focused around biomarkers (e.g. much transla-
tional psychological, social care and public
health research). Nonetheless, it is fair to argue
that the vision that drives translational research
and medicine is a vision in which biomarkers
will expedite the development of new pharma-
cological treatments as they move from animal
models through clinical testing through to
eﬀective use in humans. As the scientist Wehling
has put it:
methods and tools to facilitate the translational
process need urgently to be developed. A major
aspect in this regard is the description and assess-
ment of key indicators in a translational process,
so-called biomarkers, which are needed for trans-
lational prediction. They are the main elements in
predicting eﬃcacy and safety from animal to man
[sic] and could be seen to be accountable for 80–
90% of translational success.8
The translational pathway was initially
understood as unidirectional, moving from the
laboratory to the clinic. But researchers and
policy makers increasingly argue that the phrase
bench to bedside erroneously simpliﬁes what is
a complex and two-way process.9 There is
therefore growing recognition that knowledge
from the bedside must feed back into the lab-
oratory if the translational endeavour is to have
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any real success. Similarly, there is the growing
realization that we need to understand much
more about how and why interventions actually
reach the bedside (and the community): it is far
from guaranteed that health applications move
into real world practice.10,11 The T1 phase –
which encompasses the movement from basic
science to clinical research – has therefore been
complemented by phases T2, T3 and T4 (see
Table 1).
The divisions between phases include those of
expertise and personnel. While clinical labora-
tory-based scientists such as geneticists and
molecular biologists populate T1, phases T2–T4
demand a variety of expertise (including dis-
ease ⁄ illness-speciﬁc expertise, clinical epidemi-
ology, evidence synthesis and qualitative
research). Notably, service user and other
stakeholder participation, when mentioned at
all, are assigned to these latter phases (and often
to the very end of the pipeline). See, for example,
the inﬂuential models of translational research
developed by the Presidents Cancer Panel in
the US (Fig. 1a) and the Wellcome Trust in the
United Kingdom (Fig. 1b). The model from the
Presidents Cancel Panel in the US indicates
that advances will be disseminated to, and then
adopted by, patients and the public; the Well-
come model implies that engaging society takes
place once the products ⁄ interventions are ready
for the market. Neither indicates that patients
and the public might have signiﬁcant and active
roles to play in earlier translational phases. In
fact, while there have been multiple suggestions
about how exactly to conceptualize transla-
tional research, it is virtually unheard of for
patients and the public to be positioned any-
where but at the end of the (translational) line
(though see van den Hoonaard13 for a rare
exception).
We argue that this orthodox conceptualiza-
tion of the translational pipeline and of expertise
is ﬂawed. It conﬁnes service user and other
stakeholder participation to one small channel
and thereby ignores the potential for and bene-
ﬁts of collaborative, participatory research in all
phases of the pipeline. (Our preferred term is
service user rather than patient, though we
retain others terminological choices [e.g. the
commonly used patient beneﬁt, patient orga-
nizations, etc.]. Our phrase service users and
other stakeholders equates to the term public
as it is used and deﬁned by INVOLVE.14)
The orthodox conceptualization also implicitly
sees service users and stakeholders as recipients
of – rather than also potential generators of
– knowledge, thereby rendering invisible the
growing body of research conducted by, or in
collaboration with, service users and stakehold-
ers. (See for example the INVOLVE database
comprising research projects in the ﬁeld of
health (including public health) and social care
that have involved or plan actively to involve
members of the public as partners in the research
process.15)
In the remainder of this paper, we develop
our argument for why the orthodox model of
translational research is ﬂawed; provide scien-
tiﬁc, ethical and pragmatic reasons for why
stakeholder involvement in required in all
phases of translational research and end by
calling for a reconceptualization of translational
research in which service users and other
stakeholders are contributors to each phase of
translational research. We also brieﬂy clarify
what is required if the practice – as well as the
conceptualization – of translational research is
to include service users and other stakeholders
in all phases.
Table 1 Translational phases (adapted from Khoury et al.12)
Translational
phase Research focus of translational phase
T1 Research that seeks to move a basic
discovery into a candidate health
application.
T2 Research that seeks to move T1 research into
an actual health application, and research
that develops evidence-based guidelines.
T3 Research that seeks to move evidence-based
guidelines into health practice through
dissemination, implementation and
diffusion research.
T4 Research that seeks to move health practice
into population health impact through
outcomes research.
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We write as members of a translational aca-
demic health sciences centre (AHSC); more spe-
ciﬁcally, we are part of a biomedical research
centre in England funded by the National Insti-
tute for Health Research whose primary focus is
on biomarkers. Our argument therefore focuses
on academic translational research,16,17 and in
particular on academic biomarkers research. We
are of course aware that a huge proportion of
translational research involving biomarkers
research and medical product development is
carried out by the private sector. How to involve
service users and other stakeholders at each stage
of the development and translation process for
commercially developed products is not our
prime focus here. Our speciﬁc ﬁeld of expertise is
mental health, and we therefore draw more
readily on examples from this ﬁeld.
Why transform the model and practice of
translational research?
The scientiﬁc and the pragmatic argument
Woolf, in an inﬂuential theoretical paper on
translational research, has argued for substantial
(b) The translational research process: from mind to market
(a)
Figure 1 Models of translational research: The orthodox pipeline. (a) Translating research to reduce the burden of cancer: The
translation continuum. Source: Suzanne H Reuben, for Presidents Cancer Panel (2005) Translating Research into Cancer Care:
Delivering on the Promise. 2004–2005 Annual Report: National Cancer Institute, US Department of Health and Human Services,
National Institutes of Health. http://deainfo.nci.nih.gov/advisory/pcp/pcp04-05rpt/ReportTrans.pdf (accessed 28 August 2009)
[Permission for reproduction received from US Cancer Panel]. (b) The Translational Research Process: From Mind to Market.
Source: The Wellcome Trust, What is Translational Research? [Permission for reproduction received from Wellcome Trust].
http://www.wellcome.ac.uk/Funding/Technology-transfer/WTD027704.htm (accessed 30 August 2009).
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investment in T2 research so as to maximize T1
investments. As he puts it, Bringing a drug to
market without knowing how to bring it to
patients undermines its larger purpose and can
only diminish its proﬁtability for investors.10
But surely his argument would be better served
by ensuring that potential consumers of the drug
were involved before the drug was developed (in
the T1 phase), rather than waiting till we have a
product, but with no guarantee that it will ever
ﬁnd a market (T2–T4)? Service users could, for
example, be involved not only in the selection of
the research agenda, but on the choice of
potential drug targets, which in turn might aﬀect
design issues regarding the molecule. Consider,
for example, the development of new drugs for
psychotic disorders within psychiatry: many
service users ﬁnd some of the side eﬀects of
current medication more troubling than some of
the symptoms for which that medication is pre-
scribed.18 This opens up complex questions in
terms of how best to judge the therapeutic value
of existing and yet-to-be-developed medications
– as well as how to determine which symptoms
are most pressing when deciding on priorities for
drug development. Decisions over future drug
design ought, we believe, to take into account
service users lived experience regarding which
symptoms of the psychiatric diagnosis are most
troubling, rather than simply drawing on scien-
tiﬁc and clinical expertise vis-a`-vis what kind of
medication is likely to produce most therapeutic
value. As regards later phases within drug
development, there are grounds for optimism:
empirical research on medical technological
innovation is increasingly indicating the key role
that users can play in ensuring functionality and
usability.19–22
Indeed, there is a small but growing body of
evidence regarding the scientiﬁc beneﬁts of
involving service users and other stakeholders
throughout the translational conduit. Table 2
documents indicative research (from systematic
reviews to theoretical research) on the reasons
for embedding involvement, as well as some of
the mechanisms through which one might do so,
as regards:
1. Identiﬁcationofbiomedical researchquestions.
2. Choice of treatment targets and choice ⁄
development of outcome measures.
3. Design and assessment of medical devices ⁄
technologies.
4. Design of clinical trials (including consent
processes).
5. Organization of health services.
6. Implementation science.
The potential beneﬁts of embedding such
involvement range from improving recruitment
rates within clinical trials, to identifying new and
important research questions and ⁄or potential
hypotheses, to developing interventions that are
more likely to be taken up in the clinic and by
communities. If, as Table 2 implies, there are
both grounds for, and instances of, involving
service users in T1 and T2 research (and not just
in the phases in which attempts are being made
to disseminate such research and improve
adoption rates), then the orthodox model of the
translational pipeline needs to be transformed.
The models provided by the Wellcome Trust
and the US Presidents Cancer Panel are not
suﬃcient.
The ethical argument
The search for biomarkers lies, as we have
already noted, at the heart of translational
T4 moving
health practice 
into population 
health impact
T3 moving
evidence-based 
guidelines into 
health practice
T2 developing
an actual health 
application/
developing 
evidence-based
guidelines
T1 moving basic
discovery to 
candidate health 
application 
Service user 
and other 
stakeholder 
involvement 
(c)
Figure 1 Continued. (c) Reconceptualized model of transla-
tional research that embeds service user and stakeholder
involvement in all phases.
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research. Biomarkers promise to transform
nosology and therapeutics, for example by giv-
ing clinical status to currently sub-syndromal
symptoms, and developing new modes of early
intervention.23 Within the ﬁeld of Alzheimers
research, scientists are close to identifying a
blood biomarker that might be able to indicate
the development of Alzheimers disease many
years before the development of actual symp-
toms.24 Research such as this promises, in time,
to transform how diagnoses are made by shifting
the balance away from the current reliance on
clinical judgement and moving it towards the use
of biomarker tests (e.g. in the form of blood tests
or brain scans). It also suggests that, in time,
there will be transformations in how diseases
and disorders are separated out from one
another. Such potential transformations raise
many complex ethical and normative questions.
For example, what would be the consequences
of earlier biomarker-based diagnoses in relation
to a disease such as Alzheimers for which there
is currently no cure? Biomarkers also carry great
commercial value, and hence raise a number of
diﬃcult questions vis-a`-vis the relation between
academia and industry.25 They therefore raise
many ethical and legal questions. This can be
discerned particularly clearly in the ﬁeld in
which we work – mental health. We use the
example of mental health in this section to
clarify our arguments, as this ﬁeld is character-
ized by vigorous debate over aetiology; over the
threshold for caseness (how widely or narrowly
the criteria for any particular diagnosis ought to
be drawn);26 the acceptability of pharmacologi-
cal interventions; and which criteria to use when
assessing the success of interventions. Biomar-
kers research is likely to have implications for all
of these debates, which means that exploring the
ethical and normative implications of such
research is particularly pressing. But it is
important to realize that psychiatric biomarkers
operate through complex algorithms based
around statistical probabilities rather than cer-
tainties. They are therefore unlikely deﬁnitively
to resolve questions of aetiology or diagnosis, or
which pharmacological intervention is most
appropriate for which person. Biomarkers are,Ta
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nonetheless, likely to move rapidly through
translational channels and be used in a variety
of therapeutic and other interventions. Singh
and Rose27 have argued in a recent article in
Nature that, in the process, risk proﬁling is
likely to become ever more prevalent – e.g. the
use of biomarkers to predict which children
are likely to engage in antisocial behaviour, to
justify early and preventative pharmacological
intervention, or to underpin decisions over
childrens education. Such risk proﬁles have
the potential to aﬀect personal identity, exac-
erbate stigma and consolidate societal
assumptions about genetics, ethnic diﬀerences
and behaviour. We argue, alongside Singh
and Rose, that detailed research involving all
those likely to be aﬀected by biomarker
research must take place before translation
into and beyond the clinic. A wide range of
stakeholders – including service users – must,
in other words, be involved in the early
translational phases, given the wide range of
ethical and normative issues raised by such
research.
Ethical concerns, we emphasize, are not
restricted to mental health. Any approach to
health improvement carries assumptions about
what health, disease and disorder are, and how
best to intervene. Mol,28 in an ethnographic
study of interventions for atherosclerosis, has
shown that diﬀerent modes of diagnosis entail
diﬀerent modes of intervention (e.g. if athero-
sclerosis is diagnosed clinically as legs that
hurt on walking, then treatment might be
walking therapy; cf. if atherosclerosis is diag-
nosed through imaging as obstruction of the
vessel lumen, then treatment might entail sur-
gery). These diﬀerent approaches entail diﬀer-
ent ways of eﬀecting patient beneﬁt – and
diﬀerent criteria to judge success. Translational
biomarker research is frequently allied with
particular modes of diagnosis and particular
ways of judging patient beneﬁt. It is, as
already noted, closely allied with attempts
more precisely to target pathophysiological
pathways, and much of its impetus is directed
towards pharmacological innovation rather
than other modes of health intervention. Nei-
ther diagnostics nor therapeutics can ever be a
simply scientiﬁc procedure: each is intimately
entangled with questions of ethics and politics.
Service users, alongside many other stake-
holders, must be party to deliberations in the
T1 phase when the priorities and goals of
health research are being consolidated and
decisions over the allocation of research funds
made.
What is required to reconceptualize the
pipeline?
Models and visions that are employed within
health research and health research policy can
and do have profound consequences for which
research is funded and how research is orga-
nized. The NIHs Roadmap, which dissemi-
nated the concept of translational research to
a wide audience, has already had a profound
eﬀect on how health research is being carried
out both within and beyond the USA. If
models of translational research restrict service
user and other stakeholder involvement solely
to the end of the translational pipeline, then it
is likely that many of those involved in plan-
ning and carrying out translational research
will have little reason to question such posi-
tioning. For this reason, we believe that a
re-conceptualization of translational research is
important in bringing about potential struc-
tural and intellectual change in the actual
practice of translational research. But calling
for a conceptual and theoretical shift is unli-
kely to be suﬃcient. We recognize that one of
the most powerful ways in which to challenge
orthodox models is of course actually to start
changing practice. To give such a change in
practice the potential to have a greater eﬀect,
such a change should be accompanied by
evaluative research – to demonstrate both that
practice is changing and to ascertain what
eﬀects those changes might be having. In this
section, then, we brieﬂy indicate how existing
research on service user and stakeholder
involvement can be harnessed in the services of
challenging both the orthodox model and the
orthodox practice of translational research.
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More high-quality research on involvement in all
phases of translational research
The evidence base on the impact and beneﬁts
of service user and stakeholder involvement in
research is still small and uneven.29 The sys-
tematic review by Crawford et al.30 on
involving patients in the planning and develop-
ment of health care demonstrated that the
eﬀects of this involvement on the quality and
eﬀectiveness of services are as yet unknown. A
recent multicentre cluster randomized trial by
Guarino et al.31 showed that a consumer
modiﬁcation of a clinical consent document led
to neither beneﬁt nor harm in understanding,
satisfaction or study refusal and adherence
rates. But the constraints of the study limited
the conclusions that might be drawn from it,
and the authors argued that more research is
needed to assess the eﬀects of consumer
involvement in trial consent processes.
Much of the existing research – and therefore,
we assume, existing practices of service user and
stakeholder involvement – cluster towards the
latter phases of the translational pipeline (par-
ticularly health services research). More research
is needed on service user involvement in T1–T2
as well as on T2–T4 – as regards scientiﬁc and
other impacts, and which methods and mecha-
nisms are likely to eﬀect successful involvement.
Service users and stakeholders are not uninter-
ested in, nor absent from T1 research: members
of patients organizations have designed and led
biomedical research into rare diseases and have
contributed to setting up biobanks.32 There is
also a growing interest in using service users
experiential knowledge of diseases and disorders
to shape biomedical hypotheses and research
questions.33
Structural and organizational changes to existing
research frameworks
One of the few existing empirical investigations
of service user involvement in T1 demonstrated
that deliberate use of patients knowledge in
biomedical research will require a more struc-
tural and interactive approach to patient par-
ticipation if it is to move beyond simply ad hoc
use.33 This is likely to challenge existing research
cultures, and demand innovative ways of devel-
oping collaborative partnerships. In the Aca-
demic Health Sciences Centre in which we work,
for example, we are attempting to develop new
collaborative partnerships that will encourage
the use of patients ⁄ service users knowledge and
expertise in biomedical research.34 Changing
research cultures and developing new collabo-
rative partnerships is undoubtedly a diﬃcult and
slow process. But it is worth bearing in mind
that the development of new research collabo-
rations and new cultures of sharing expertise
across hitherto separate domains is precisely
what the translational endeavour is designed to
bring about.
We are sanguine about the resistance that will
undoubtedly face attempts to establish service
user involvement in T1 and T2 research. Existing
literature that addresses such barriers – as well
as our own attempts within the translational
Academic Health Sciences Centre in which we
work – point to a number of intractable diﬃ-
culties. These include signiﬁcant asymmetries in
power between scientists and service users, the
prevalence amongst scientists of a knowledge
deﬁcit model whereby they perceive their role as
one of simply educating service users about the
complexities of basic and translational research;
many scientists lack of conviction that service
user involvement has the potential to contribute
scientiﬁcally to such research; the dominance of
positivist scientiﬁc paradigms that preclude
engagement with experiential knowledge and
anxiety that service users lack the requisite
objectivity and familiarity with high-level
abstraction adequately to participate.35,36 These
diﬃculties notwithstanding, we would remind
readers of the trajectory that service user
involvement has taken in applied health research
over the last two decades. While resistance to
involvement undoubtedly remains, many health
services and public health researchers have, over
the years, been persuaded of the scientiﬁc ben-
eﬁts of such involvement – whether through the
experience of working with service users and
patients, through the growing scientiﬁc stature
Service users in translational research, F Callard, D Rose and T Wykes
 2011 Blackwell Publishing Ltd Health Expectations, 15, pp.389–400
397
of research that has involved service users ⁄
patients, or through the impact that such
involvement has had on the design, practice and
dissemination of health research.14 We are
hopeful that the domain of translational
research might experience a similar journey.
Conclusion
Zerhouni,37 the NIH director who spearheaded
translational research, explicitly included par-
ticipation as one of his 4Ps of current medicine;
the others are pre-emption, prevention and
personalization. Personalization of medical
interventions is likely to be most eﬀective, we
argue, when the design of those interventions
has not taken place at a great distance from
those individuals who, it is hoped, will ulti-
mately beneﬁt from them. But much transla-
tional research restricts the question of
participation to (i) improved recruitment and
retention of subjects in clinical trials and (ii)
dissemination and adoption of health appli-
cations in the latter translational phases. We
have argued that restricting participation to
these two arenas is likely to have deleterious
eﬀects on the translational endeavour:
1. through the failure to capitalize on the many
scientiﬁc contributions that service users
might bring to translational research in its
earlier phases;
2. through the likelihood that many transla-
tional outputs will not be appropriately
designed for their end users; and
3. through lack of interrogation of ethical
questions raised by biomarker research and
funding.
There is, then, a compelling need to challenge
the dominant model and practice of participa-
tion if the potential of translational research is
fully to be realized.
Translational research is being held out as an
almost compulsive win–win situation in terms
of beneﬁts to patients and ﬁnancial beneﬁts.38
For patients to beneﬁt from research, they
arguably need (i) the outputs of research (the
intervention) to be easily available and usable,
(ii) the intervention eﬀectively to address a
problem that they consider pressing and ⁄or
distressing, (iii) the treatment regimen to be
tailored to the realities of their daily life39 and
(iv) the form the intervention takes to ﬁt – more
or less – with their values as regards the horizon
of health, as well as acceptable levels of intru-
sivity and ⁄or side-eﬀects. For the win–win sit-
uation of ﬁnancial as well as patient beneﬁt to
move from rhetoric to reality, translational
research must therefore ensure that service users
are embedded within every component of
translational research.
Figure 1c presents a new model of transla-
tional research that indicates how such research
might be both conceptualized and practised if
this were the case. Instead of a pipeline, it is
constructed as an interlocking loop with service
user and stakeholder involvement feeding into
each element (T1, T2, T3 and T4). There is,
notably, two-way interaction between each ele-
ment – including service user and stakeholder
involvement – within the model. Undoubtedly
the model requires ﬁne-tuning and development
through further empirical and theoretical
research. The original NIH Roadmap charted,
as any roadmap does, a direction for travel
rather than a completed journey. In a similar
way, our reconceptualized model of transla-
tional research presented in Fig. 1c is envisaged
as a starting-oﬀ point in conceptualizing service
user involvement in translational research rather
than as a ﬁnal destination.
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